These drugs have shown remarkable efficacy in both first-line and follow-up treatment, significantly improving patient survival and quality of life, and firmly establishing their status as cornerstone therapies for breast cancer treatment, and the overall safety profile of CDK4/6 inhibitors is validated by extensive clinical studies. Here, CDK4 is linked to breast carcinoma.